Dise Plus

Quick links to important sections

Dise Plus

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dise Plus

Property Description
Active ingredient Paracetamol (Acetaminophen)
Forms Oral solid (tablet, capsule), Oral liquid, Rectal
Pharmacological class Non-opioid analgesic and antipyretic
Common use Relief of mild-to-moderate pain and fever reduction
Origin Synthetic (Chemically derived)

What Type of Medicine is Dise Plus (Paracetamol)?

Dise Plus refers to a medicinal preparation containing the active ingredient Paracetamol, which is fundamentally classified as a non-opioid analgesic and an antipyretic. The substance is widely used globally and maintains an established therapeutic value.

The active ingredient, Paracetamol, is a synthetic compound also known as Acetaminophen (N-acetyl-p-aminophenol), an aniline derivative. This pharmacological classification differentiates it from the NSAIDs (Nonsteroidal Anti-inflammatory Drugs), as Paracetamol's action is centrally mediated. Its pharmacological profile is characterized by rapid absorption and the inhibition of pain perception in the central nervous system.

Composition, Origin, and Available Forms

The composition of Dise Plus is characterized by the presence of Paracetamol as the single active ingredient, combined with a necessary excipient base/vehicle. Its origin is synthetic, resulting from chemical manufacturing processes. This medication is presented in numerous pharmaceutical forms to facilitate various routes of administration, including oral solid preparations like tablets and capsules, as well as oral liquid preparations such as suspensions, and forms designed for rectal use.

The Primary Benefit of Using Paracetamol

The core benefit of taking the Dise Plus preparation is the targeted alleviation of mild-to-moderate pain and the effective reduction of fever. Paracetamol's physiological action enables the body to achieve pain relief by influencing pain signals and assists the body's thermoregulatory center to lower an elevated temperature. This dual utility makes it a standard option for symptomatic relief. A common neutral use scenario involves managing temporary discomfort, such as the aches and elevated temperature associated with a common cold.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. Acetaminophen - StatPearls - NCBI Bookshelf

What side effects are possible with Dise Plus?

Possible Side Effects and Safety Information

The official safety profile for the active ingredient in Dise Plus, Paracetamol (Acetaminophen), is structured by regulatory authorities around documented adverse reactions, frequency classifications, and specific safety constraints. Most side effects are categorized as Rare or Very Rare according to the established regulatory frequency standards.

Adverse reactions documented in official labeling primarily affect specific System-Organ Classes:

  • Hepato-biliary Disorders: Includes reports of abnormal liver function and the risk of severe hepatic injury (liver damage or failure), which is the most critical safety concern.
  • Blood and Lymphatic System Disorders: Includes rare reactions such as thrombocytopenia, agranulocytosis, and leukopenia.
  • Immune System Disorders and Skin: Documented serious reactions include anaphylactic shock (severe allergic reaction) and severe cutaneous adverse reactions (SCARs) like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Renal and Urinary Disorders: Reports include specific adverse events like acute tubular necrosis, typically associated with very rare events or prolonged use.

Regulatory documentation notes that risks are associated with dose and exposure. The primary safety constraint is the absolute prohibition against exceeding the maximum recommended daily limit and avoiding the concomitant use of any other product containing Paracetamol to prevent severe, potentially fatal hepatic injury. Furthermore, caution is documented for use in specific patient groups, including individuals with pre-existing severe hepatic impairment or severe renal impairment.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose of Dise Plus, which contains paracetamol, presents initially with non-specific signs such as Nausea, Vomiting, Anorexia, Pallor, and Abdominal pain. Regulatory documentation notes that these early manifestations may be transient, potentially masking the progression of severe internal toxicity.

The most serious outcomes are typically delayed and involve primary damage to the liver, leading to Acute liver failure and Hepatic necrosis. Documented life-threatening complications include Hepatic encephalopathy, Coma, and Acute renal tubular necrosis. Individuals with conditions such as chronic alcoholism or malnutrition are noted in official labeling to have an increased susceptibility to severe hepatotoxicity.

Emergency Action and Treatment

Government regulatory authorities mandate that emergency medical attention must be sought immediately upon any suspected overdose, regardless of whether initial symptoms are present. This urgent action is required due to the potential for delayed, life-threatening progression of toxicity.

Management, as described in official prescribing information, focuses on symptomatic and supportive treatment. N-acetylcysteine (NAC) is the specific antidote, and its administration is time-critical. Close hospital monitoring is required, specifically tracking plasma paracetamol concentration, hepatic function (AST/ALT), and coagulation status (INR/Prothrombin Time).

Therapeutic Uses of Dise Plus

The medication is a widely utilized agent applied across domains where additional symptomatic support is needed for pain and fever.

Symptomatic Relief of Mild-to-Moderate Pain

This medication is commonly used in conditions characterized by episodic or fluctuating symptom patterns and is relevant for easing symptoms related to physical discomfort. It may assist with managing symptoms that create noticeable functional strain, providing support that helps ease the symptom load of temporary aches. Common therapeutic indications include relief for headaches, dental pain, muscular aches, and menstrual discomfort.

Management of Fever and Acute Episodes

Dise Plus is also applied across domains where increased discomfort is present due to elevated body temperature. It is relevant for easing symptoms related to systemic imbalance by helping with the fever and the associated generalized malaise that can accompany acute or disruptive episodes. Applied in settings marked by temporary physiological imbalance, it contributes to improved comfort during periods of heightened symptoms, such as those following immunizations or minor procedures.


Quick Fact: Symptomatic Support for Pain and Fever Dise Plus plays a role in managing symptoms related to mild-to-moderate pain and pyrexia (fever), providing short-term symptomatic assistance that contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH StatPearls overview of Acetaminophen

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Dise Plus (Paracetamol) — Official Regulatory Information

Eligibility Scope Status / Regulatory Wording
Populations for whom use is allowed Most people aged 16 and over; generally eligible for adults and adolescents aged 12 and over.
Populations for whom use is not recommended Children under 3 months old, unless specifically instructed by a doctor.
Populations for whom use is contraindicated Individuals with known hypersensitivity to paracetamol or excipients; patients with severe hepatic impairment or severe active liver disease.

Age and Condition-Specific Eligibility Rules

Age-Related Eligibility: Must not be used in babies less than 3 months old without medical guidance. No need for routine dosage reduction is typically specified for the elderly population.

Condition-Specific Eligibility:

  • Severe Hepatic/Renal Impairment: Use requires caution and may necessitate reducing the maximum daily intake or extending the dose interval.
  • Chronic Risk Factors: Caution is advised for patients with chronic alcoholism, dehydration, chronic malnutrition, or those who weigh less than 50 kg, as these factors can restrict use.

Pregnancy and Lactation Eligibility: Use is generally permitted during pregnancy when clinically necessary, utilizing the lowest effective dose for the shortest duration. The medicine is also considered compatible with breastfeeding.


Connection to the overall eligibility profile: Regulatory documents define eligibility by establishing absolute contraindications (e.g., severe active liver disease) and detailing conditional use restrictions related to specific comorbidities and risk factors (e.g., severe renal impairment). This framework also sets clear age boundaries for safe use, independent of any therapeutic claims.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Dise Plus (Paracetamol/Acetaminophen) is defined by pharmacokinetic and pharmacodynamic interactions documented in regulatory labeling.

Contraindicated Combinations

Co-administration with any other medicinal product containing Paracetamol is strictly prohibited to prevent the risk of acute overdose and subsequent severe hepatotoxicity.

Pharmacokinetic and Clearance Interactions

Several medicines are documented to alter the exposure of Paracetamol. Probenecid reduces the clearance of Paracetamol by inhibiting its conjugation, resulting in increased plasma concentrations. Conversely, medicines that induce liver enzymes, such as Rifampicin and Phenytoin, are listed as potentially increasing the severity of overdose by accelerating the formation of the toxic metabolite.

Absorption can be modified by co-administered drugs: Metoclopramide and Domperidone increase the absorption rate, while Cholestyramine reduces it. Due to this effect, Cholestyramine must not be administered within one hour of Paracetamol.

Pharmacodynamic and Substance Interactions

Prolonged regular use of Paracetamol may enhance the effect of Warfarin and other coumarin anticoagulants, increasing the risk of bleeding. Co-administration with Flucloxacillin carries a documented risk of Metabolic Acidosis in patients with specific risk factors for glutathione depletion. Additionally, excessive or chronic consumption of alcohol is a documented risk factor for hepatotoxicity when combined with this medicine.

Mechanism of Action

The mechanism of action for the active ingredient, Paracetamol, is understood to be centrally mediated, influencing specific pathways primarily within the central nervous system (CNS).


Central Inhibition of Prostaglandin Synthesis

The core mechanism involves the reversible inhibition of Cyclooxygenase (COX) enzymes, predominantly the COX-2 isoenzyme, within the CNS. This selective action restricts the synthesis of the inflammatory mediator, Prostaglandin E2 (PGE2), in the brain and spinal cord. This is the initial molecular step that precedes the subsequent physiological outcomes.

Hypothalamic Thermoregulation Reset

By limiting PGE2 production in the hypothalamic thermoregulatory center, the drug effectively prevents the elevation of the body’s set point, which is typically driven by pyrogens. The physiological consequence is the activation of vasodilation and sweating, initiating the sequence of physiological events that result in the lowering of an elevated set point.

Dual-Pathway Modulation of Nociceptive Signals

The drug's influence on pain pathways involves two complementary central actions: reduced PGE2-mediated sensitization of pain pathways in the spinal cord, combined with an indirect enhancement of descending serotonergic inhibitory pathways. This dual modulation dampens the transmission and intensity of nociceptive signals, modulating the transmission of these signals in the CNS.

Dosage and Administration Information

The official administration of Dise Plus (Paracetamol/Acetaminophen) is precisely defined by established guidelines governing the route, dosage, frequency, and duration of use. The medication is approved for Oral (tablets, liquids), Rectal (suppositories), and Intravenous (IV) routes, with IV use typically restricted to clinical settings when the oral route is not feasible.


Official Administration Guidelines

Instruction Category Regulatory Statement
Standard Dosing The typical single oral dose for adults is 500 mg to 1000 mg. The Maximum Total Daily Dose from all Paracetamol-containing products combined must not exceed 4000 mg (4 grams).
Dosing Frequency Doses should be taken only as needed, with a required minimum interval of 4 hours between administrations. The total number of doses must not exceed four in a 24-hour period.
Dosing Adjustments Dosing for children is strictly weight-based (e.g., 10 to 15 mg/kg per dose). For patients with severe renal impairment (kidney disease), the minimum dosing interval should be extended to at least 6 hours.
Context of Use Paracetamol may be taken with or without food. Liquid or dissolvable forms must be measured using a calibrated device or fully dissolved in water, respectively.
Use Constraint To prevent exceeding the maximum daily dose, patients must not use multiple products containing Paracetamol concurrently. The medicine is authorized for short-term symptomatic relief only.

This framework specifies the means of delivery, defines the precise quantity limits, and sets the required timing for administration, ensuring adherence to the standardized protocol outlined in health agency labeling.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dise Plus

This overview summarizes what is known and what is still uncertain about the research exploring the use of Dise Plus (Paracetamol/Acetaminophen), based on scientific studies and evidence reviews. It describes the specific conditions and populations that have been the focus of clinical research.


Evidence for Relief of Mild-to-Moderate Pain

Dise Plus was studied for outcomes related to physical discomfort. Research in this area primarily consists of systematic reviews that combined data from Randomized Controlled Trials (RCTs), which are study designs used to assess short-term or episodic symptom patterns.

Research on Osteoarthritis and Acute Pain Contexts

For adults with conditions marked by functional limitations, such as pain associated with knee or hip osteoarthritis, research has examined patient-reported outcomes describing perceived discomfort and daily functioning. Findings describe patterns observed in the studies related to measured changes in pain scores when comparing the medication to placebo. Research contributes to understanding short-term changes, but the magnitude of the measured change was observed in some studies to be small. The follow-up durations were limited in these primary trials.

Research on Conditions Showing Limited Evidence

Dise Plus was evaluated in specific conditions involving periods of heightened symptoms, such as acute, non-specific low back pain (LBP). In this specific scenario, data show patterns related to outcomes for recovery and functional disability that were similar when comparing the medication group to the placebo group. Studies report how symptoms evolved in the observed populations, indicating no distinct patterns related to a measured change in this context.


Evidence for Fever Reduction (Antipyretic Use)

In pediatric populations, studies reported that the medication was associated with measured changes in body temperature compared to inactive treatment. In adult populations, especially in critical care contexts, studies observed only a brief fluctuation in temperature, and outcomes monitoring physiological strain, such as measures of patient stability, did not reflect an observed pattern of change.


What Remains Uncertain About Dise Plus Research

The body of evidence, while extensive for certain uses, still contains research limitation frames. The long-term outcomes are not fully established, and evidence offers limited detail on the consistency of observed patterns over extended periods of time. Data for certain groups remain insufficient, including those exploring use during pregnancy-related periods. Research highlights what is known—and what is still uncertain—across the entire evidence landscape.

Key Studies & References Acetaminophen (StatPearls)

Frequently Asked Questions (FAQ)

Common questions about Dise Plus (FAQ)

Q: How is Dise Plus different from other similar treatments mentioned in general discussions?

Dise Plus contains an active ingredient that is classified as a non-opioid analgesic and an antipyretic. Its mechanism of action is primarily central, meaning it influences pain and fever pathways in the central nervous system. Unlike common non-steroidal anti-inflammatory drugs (NSAIDs), official information indicates it does not have significant anti-inflammatory activity.

Q: What are the most common side effects reported in clinical trials for Dise Plus?

Official regulatory safety lists document adverse reactions, but they primarily focus on the rare and serious events, such as severe hepatic injury. The majority of reported side effects, when the drug is administered as directed, are categorized as rare or very rare.

Q: What are the known long-term effects of taking Dise Plus regularly?

The long-term outcomes and consistency of patterns over extended periods are described in research limitation frames as not fully established. However, regulatory warnings note that chronic use is associated with a risk of severe liver injury and potential rare renal (kidney) disorders, especially if the maximum daily limits are observed.

Q: Are there any specific foods or non-alcoholic drinks that should be avoided while using Dise Plus?

Official patient information states that the medicine may be taken with or without food, and there are no specific restrictions for non-alcoholic drinks listed. Regulatory warnings indicate that excessive or chronic consumption of alcohol is a documented risk factor for increased liver injury.

Q: What is the expected time frame to see the full potential benefit of Dise Plus treatment?

Studies indicate the medicine is rapidly absorbed after being taken orally. Therapeutic levels, which correspond to when relief begins to be perceived, are typically reached within a window of 30 minutes to 2 hours following administration.

Q: Can Dise Plus be used for conditions other than its primary approved indication?

Regulatory approval confirms the medicine is authorized only for its labelled uses (mild-to-moderate pain and fever reduction). Any non-approved use is considered off-label.

Q: Is it normal to experience mild nausea when first starting Dise Plus?

Regulatory safety documents list gastrointestinal adverse effects, such as nausea or abdominal pain, as extremely uncommon when compared to other types of analgesic medicines.

Q: Is a headache listed as a commonly reported side effect of Dise Plus?

In official adverse event reporting databases, headache is generally not listed among the common or very common side effects when the medicine is used at its recommended therapeutic dose.

Q: Do herbal supplements or vitamins have a documented effect on how Dise Plus works?

Patient information mentions the importance of communicating all vitamins and supplements taken to a healthcare professional. Certain supplements may affect the drug's metabolism, and official warnings indicate this could potentially increase the risk of liver damage.

Q: What is officially documented about stopping the use of Dise Plus suddenly?

This medicine is authorized for short-term symptomatic relief only and is not classified as an opioid. Therefore, regulatory documents do not typically include warnings about discontinuation or withdrawal symptoms when use is stopped.

Q: How long does the main compound of Dise Plus stay in the body's system after the last intake?

Pharmacokinetic studies summarized by health organizations indicate that the drug has an elimination half-life of approximately two hours in the body under normal therapeutic conditions.

Q: Is there a restriction for people with a history of heart issues using Dise Plus?

Official labeling documents the need for caution in certain patient subgroups. High or chronic use has been associated in some reports with a slight, statistically significant increase in blood pressure and heart rate.

Q: Does Dise Plus require any special monitoring or routine lab tests while it is being used?

For short-term use at recommended doses, routine monitoring is generally not required. Clinical guidelines indicate that regular monitoring for liver toxicity may be considered for patients taking the medicine consistently over a long period.

Q: Is Dise Plus classified as a habit-forming drug or a controlled substance?

The single-ingredient formulation of the medicine is not classified as a controlled substance by regulatory agencies. It is also not generally associated with a habit-forming risk.

Q: What is the standard procedure described in patient leaflets if a dose of Dise Plus is missed?

Patient information describes the process as taking the dose as soon as the missed dose is remembered. The stated minimum interval (e.g., 4 hours) must be maintained before the next administration, and regulatory limits on the maximum daily dose must be observed.

Q: Does the official labeling of Dise Plus include a serious regulatory warning, such as a Black Box Warning?

Yes, official labeling for all prescription drug products containing Acetaminophen in the United States requires a Boxed Warning (sometimes called a Black Box Warning). This warning highlights the potential for severe liver injury.

Q: Do I need a special type of prescription or authorization to be dispensed Dise Plus?

The medicine is widely available in many countries as an Over-the-Counter (OTC) product, which means it can be obtained without a prescription. This applies to single-ingredient formulations sold within regulated dose constraints.

Q: Is there an official warning about taking Dise Plus with grapefruit or grapefruit juice?

No, regulatory drug interaction databases and official labeling do not list grapefruit or grapefruit juice as having a significant interaction that requires a warning for this medicine.

Q: What is the functional difference between the brand name and generic versions of Dise Plus?

According to drug monographs, generic versions must demonstrate bioequivalence to the brand-name product. This regulatory requirement ensures that the generic product contains the identical active ingredient, strength, and dosage form, and is required to work the same way in the body.

Q: Is there information regarding potential interactions between Dise Plus and hormonal birth control pills?

Regulatory information indicates that Dise Plus generally has no known significant interaction that would reduce the effectiveness of hormonal birth control pills. This means standard use is typically compatible.

How should Dise Plus be stored and disposed of?

The storage and disposal of this medicine, which contains Paracetamol (Acetaminophen), must align strictly with government regulatory requirements to ensure product integrity and public safety.

Category Regulatory Storage/Disposal Requirement
Temperature Store at Controlled Room Temperature (typically 20°C to 25°C, or 68°F to 77°F).
Protection Keep the product in the original, tightly closed container and protect from excessive heat, moisture, and light. Liquid forms must be kept from freezing.
Child Safety Mandatory requirement to store the medicine out of the sight and reach of children.
Disposal Discard unused or expired product via an official drug take-back program or by following the specific household disposal steps (mixing with undesirable substances and sealing in a bag). Do not dispose of into wastewater.

Storage under these conditions maintains the product's stability until the labeled expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dise Plus found in:

A-Z Index: